Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT
P.M. Burger(University Medical Center Utrecht), Frank L.J. Visseren(University Medical Center Utrecht), S Koudstaal, Arend Mosterd(Werkgroep Cardiologische centra Nederland), Philippe Gabríel Steg(Mount Sinai Hospital), Fabrice M A C Martens(Deventer Ziekenhuis), Jannick A N Dorresteijn(Utrecht University), Deepak L. Bhatt(Mount Sinai Hospital)
Cited by 0
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2021|6.1k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k